Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study

M de Boer; R de Wit; G Stoter; J Verweij

doi:10.1007/BF01202225

Possible lack of full cross-resistance of 5HT3 antagonists; a pilot study

J Cancer Res Clin Oncol. 1995;121(2):126-7. doi: 10.1007/BF01202225.

Authors

M de Boer¹, R de Wit, G Stoter, J Verweij

Affiliation

¹ Department of Medical Oncology, Rotterdam Cancer Institute/Dr. Daniel den Hoed Kliniek, The Netherlands.

PMID: 7883775
DOI: 10.1007/BF01202225

Abstract

We investigated the potential of cross-over to the serotonin receptor (5HT3) antagonist ondansetron after protection failure with tropisetron. Several cases of complete protection were observed. These limited data suggest that there is an indication for retreatment with a different 5HT3 antagonist after an initial failure to another and also stress the need and relevance for comparative studies between 5HT3 antagonists.

Publication types

Clinical Trial
Clinical Trial, Phase II

MeSH terms

Adult
Aged
Antiemetics / therapeutic use*
Cisplatin / adverse effects
Cross-Over Studies
Drug Resistance
Female
Humans
Indoles / therapeutic use*
Male
Middle Aged
Nausea / prevention & control
Ondansetron / therapeutic use*
Pilot Projects
Serotonin Antagonists / therapeutic use*
Tropisetron
Vomiting / prevention & control

Substances

Antiemetics
Indoles
Serotonin Antagonists
Ondansetron
Tropisetron
Cisplatin